This company listing is no longer active
RGDX.Q Stock Overview
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Response Genetics, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -99.96% |
| 5 Year Change | -99.90% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| RGDX.Q | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -1.7% |
| 1Y | n/a | -4.0% | 22.9% |
Return vs Industry: Insufficient data to determine how RGDX.Q performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how RGDX.Q performed against the US Market.
Price Volatility
| RGDX.Q volatility | |
|---|---|
| RGDX.Q Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RGDX.Q has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RGDX.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | n/a | www.responsegenetics.com |
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites.
Response Genetics, Inc Fundamentals Summary
| RGDX.Q fundamental statistics | |
|---|---|
| Market cap | US$38.00 |
| Earnings (TTM) | -US$14.21m |
| Revenue (TTM) | US$16.62m |
0.0x
P/S Ratio0.0x
P/E RatioIs RGDX.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGDX.Q income statement (TTM) | |
|---|---|
| Revenue | US$16.62m |
| Cost of Revenue | US$10.37m |
| Gross Profit | US$6.25m |
| Other Expenses | US$20.46m |
| Earnings | -US$14.21m |
Last Reported Earnings
Mar 31, 2015
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RGDX.Q perform over the long term?
See historical performance and comparison